( CHICAGO--(BUSINESS WIRE)--Jun 4 2007 -...)Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer,Health

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA) today announced updated results from a joint analysis of two Phase III clinical trials studying Herceptin(R) (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer. Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) showed that, with median follow-up of nearly three years, the addition of Herceptin to standard adjuvant therapy significantly improved overall survival in women with HER2-positive, node-positive breast cancer, compared to patients who received standard adjuvant therapy alone. Herceptin (with chemotherapy) is the first and only HER2-targeted therapy to demonstrate an overall survival benefit in adjuvant breast cancer, based on these study results, and in first-line metastatic HER2-positive breast cancer.

"These findings show, when using Herceptin for the adjuvant treatment of women with HER2-positive, node-positive breast cancer, patients live longer," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. "These data further reinforce the use of Herceptin and chemotherapy as the foundation of care for women with this aggressive form of the disease."

Edith Perez, M.D., director of Mayo Clinic's Multidisciplinary Breast Clinic in Jacksonville, Fla., presented these updated data from the joint analysis of NCCTG N9831 and NSABP B-31 (Abstract #512 -- Monday, June 4, 2007, 9 a.m. CDT) studying Herceptin in the adjuvant setting. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

These two randomized, controlled Phase III studies evaluated four cycles of doxorubicin and cyclophosphamide followed by paclitaxel, either every t
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival